Immunomodulation of Bu-Zhong-Yi-Qi-Tang on In Vitro Granulocyte Colony-Stimulating-Factor and Tumor Necrosis Factor-α Production by Peripheral Blood Mononuclear Cells

References

• Longo L., Donti E., Mencarelli A., Avanzi G., Pegoraro L., Alimena G., Tabilio A., Venti G., Grignani F., Pelicci P. G. Mapping of chromosome 17 breakpoints in acute myeloid leukemias. Oncogene 1990; 5: 1557
   PubMed Web of Science ®Google Scholar
• Harmenberg J., Hoglund M., Hellstrom-Lindber E. Eur. J. Haematol. G-and GM-CSF in oncology and oncological haematology 1994; 55: 1
   Google Scholar
• Henon P. R., Becker M. Cytokine enhancement of peripheral blood stem cells. Stem Cells 1993; 11: 65
   PubMedGoogle Scholar
• Hiroyoshi F., Tsuyoshi H., Kazuhiko H., Tetsushi T. An application of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in the case of hepatocellular carcinoma combined with liver cirrhosis in which leukopenia developed after chemoembolization. Gastroenterol. Japonica 1991; 26: 779
   PubMedGoogle Scholar
• Takashi H., Seishiro W., Mikio N., Takashi M., Satoshi T., Motoo S. Combination immunotherapy with OK-432, recombinant granulocyte-colony-stimulating factor and recombinant interleukin-2 for human hepatocellular carcinoma, Cancer Immunol. Immunother. 1996; 42: 127
   Google Scholar
• Cannistra S. A., Griffin J. D. Regulation of the production and function of granulocytes and monocytes. Semin. Hematol. 1988; 25: 173
   PubMed Web of Science ®Google Scholar
• Kapp A., Zeck-Kapp G. J. Activation of the oxidative metabolism in human polymorphonuclear neutrophilic granulocytes: the role of immuno-modulating cytokines. J. Invest. Dermatol. 1990; 95: 94S
   PubMed Web of Science ®Google Scholar
• Haworth C. Multifunctional cytokines in haemopoiesis. Blood Rev. 1989; 3: 263
   PubMedGoogle Scholar
• Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 1975; 72: 3666
   PubMed Web of Science ®Google Scholar
• Tracey K. J., Vlassara H., Cerami A. Cachectin/tumour necrosis factor. Lancet 1989; 1: 1122
   PubMed Web of Science ®Google Scholar
• Grau G. E., Modlin R. L. Immune mechanisms in bacterial and parasitic diseases: protective immunity versus pathology. Curr. Opin. Immunol. 1991; 3: 480
   PubMedGoogle Scholar
• Dunn D. L. Use of novel therapeutic agents for the treatment of serious infection. Am. J. Surg. 1993; 166: 449
   PubMedGoogle Scholar
• Pasparakis M., Alexopoulou L., Douni E., Kollias G. Tumour necrosis factors in immune regulation: everything that's interesting is…new. Cytokine Growth Factor Rev. 1996; 7: 223
   PubMedGoogle Scholar
• Fan S. T., Mackman N., Cui M. Z., Edgington T. S. Integrin regulation of an inflammatory effector gene. Direct induction of the tissue factor promoter by engagement of beta 1 or alpha 4 integrin chains. J. Immunol. 1995; 154: 3266
   PubMed Web of Science ®Google Scholar
• Teichmann J. V., Ludwig W. D., Thiel E. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor. Leuk. Res. 1992; 16: 287
   PubMed Web of Science ®Google Scholar
• Harada Seta M., Ito K., Tamada O., Li K., Terao T., Takenoyama H., Kimura M., Nomoto G. K. Concomitant immunity against tumor development is enhanced by the oral administration of a kampo medicine, Hochu-Ekki-To (TJ-41: Bu-Zhong-Yi-Qi-Tang), Immunophamacol. Immunotoxicol. 1995; 17: 687
   PubMedGoogle Scholar
• Li X. Y., Takimoto H., Miura S., Yoshikai Y., Matsuzaki G., Nomoto K. Effect of a traditional Chinese Medicine. Bu-Zhong-Yi-Qi-Tang (Japanese name: Hochu-ekki-to) on the protection against Listeria monocytogenes infection on mice, Immunopharmacol. & Immunotoxicol. 1992; 14: 383
   Google Scholar
• Cho J. M., Sato N., Kikuchi K. Prophylactic anti-tumor effect of Hochu-ekki-to (TJ41) by enhancing natural killer cell activity. In Vivo 1991; 5: 389
   PubMedGoogle Scholar
• Hardin T. C., Koeller J. M., Kuhn J. G., Roodman G. D., Von Hoff D. D. Nutritional parameters observed during 28-day infusion of recombinant human tumor necrosis factor-alpha. J. Parenter. Enteral Nutr. 1993; 17: 541
   PubMedGoogle Scholar
• Hirofuji H., Kakumu S., Fuji A., Ohtani Y., Murase K., Tahara H. Natural killer and activated killer activites in chronic liver disease and hepatocellular carinoma: evidence for a decreased lymphokine-induced activity of effector cells. Clin. Exp. Immunol. 1987; 68: 348
   PubMed Web of Science ®Google Scholar
• Kakumu S., Hara T., Gohji H., Sakamoto N. Inhibition of lymphocyte cytotoxicity in chronic active hepatitis. Clin. Exp. Immunol. 1978; 33: 71
   PubMedGoogle Scholar
• Shirai M., Watanabe S., Nishioka M. Antitumour effect of intratumoral injection of human recombinant interleukin-2 in patients with hepatocellular carcinoma: a preliminary report. Eur. J. Cancer 1990; 26: 1045
   PubMed Web of Science ®Google Scholar
• Charpentier B., Franco D., Paci L., Charra M., Martin B., Vuitton D., Fries D. Deficient natural killer cell activity in alcoholic cirrhosis. Clin. Exp. Immunol. 1984; 58: 107
   PubMedGoogle Scholar
• James S. P., Jones E. A. Abnormal natural killer cytotoxicity in primary biliary cirrhosis: evidence for a functional deficiency of cytolytic effector cells. Gastroenterology 1985; 89: 165
   PubMedGoogle Scholar
• Wanebo H. J. Tumor necrosis factors. Semin. Surg. Oncol. 1989; 5: 402
   PubMedGoogle Scholar
• Mittelman A. Life-threatening toxicity of cancer therapy. Crit. Care Clin. 1988; 4: 1
   PubMedGoogle Scholar
• Wagstaff J., Melief K. J. Lymphokines and cytokines. Cancer Chemother. Biol. Response Modif. 1987; 9: 432
   PubMedGoogle Scholar